Addex Therapeutics

Addex Therapeutics Ltd. is a biopharmaceutical company, which engages in the development of drugs for human health. It develops novel, orally available, and small molecule allosteric modulators for neurological disorders. Its pipeline includes Dipraglurant, ADX71149, GABAB PAM, mGlu7 NAM, mGlu2 NAM, mGlu4 PAM, and mGlu3 PAM. The company was founded by Vincent Mutel, Timothy Dyer, and Mark Epping-Jordan in 2002 and is headquartered in Geneva, Switzerland.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Addex Therapeutics (ADXN) has been struggling lately, but the selling pressure may be coming to an end soon.

Addex Therapeutics (ADXN) Sees Hammer Chart Pattern: Time to Buy?

Ge neva, Switzerland, May 5 , 20 2 1 – Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, today reported financial results for the quarter ended March 31, 2021 and provided a corporate update.

Addex Reports Q1 2021 Financial Results and Provides Corporate Update

Addex Therapeutics Limited (ADXN) CEO Tim Dyer on Q4 2020 Results - Earnings Call Transcript

KYIV, Ukraine--(BUSINESS WIRE)--Enamine Ltd. a provider of drug discovery services empowered with the world's largest collections of building blocks, fragments and screening compounds announced today that it has extended its long-standing research collaboration with Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company specialized in allosteric modulation-based drug discovery and development. Enamine is providing Addex with its integrated capability in med

Enamine Extend Collaboration With Prominent Swiss Biotech

Obalon Therapeutics

Genetic Technologies

Genetic Technologies (NASDAQ: GENE) shares are trading higher after the company provided an update on its COVID-19 severity risk test, saying predictive capabilities improved 100% over age and sex alone. Genetic Technologies is an Australia-based molecular diagnostics company which offers predictive testing and assessment tools to help physicians proactively manage women's health.

Why Addex, Genetic Technologies And Obalon Are Moving Today

Addex Therapeutics (ADXN) stock is soaring higher on Thursday after announcing news concerning a clinical trial for its epilepsy drug. The post Epilepsy Drug News: Why Addex Therapeutics (ADXN) Stock Is Soaring Today appeared first on InvestorPlace.

Epilepsy Drug News: Why Addex Therapeutics (ADXN) Stock Is Soaring Today

The stock price of Addex Therapeutics (NASDAQ: ADXN) is trading at more than 50% pre-market today. This is why it happened.

ADXN Stock Price Increases Over 50% Pre-Market: Why It Happened

Geneva, Switzerland, January 7, 2021 – Addex Therapeutics Ltd (SIX: ADXN and Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today the pricing of an underwritten global offering of 6,000,000 registered shares (the New Shares) (including shares in the form of American Depositary Shares, or ADSs) at a public offering price of approximately CHF1.47 per share or $10.00 per ADS. Each ADS represents the right to receive six shares of Addex.  The aggregate gross proceeds from the offering are expected to be $10.0 million, before deducting the underwriting discounts and commissions and offering expenses payable by Addex. The offering is expected to close on or about January 11, 2021, subject to satisfaction of customary closing conditions.

Addex Announces Pricing of $10.0 Million Global Offering

News for Addex Therapeutics Stock (ADXN)